Avalo Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Robert Driscoll initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $18 price target Discover the ...
Wedbush Remains a Buy on BioMarin Pharmaceutical (BMRN)
In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...
Palantir Stock: Why One Analyst Says to Buy the Dip
Palantir stock is continuing to slide Thursday as investors weigh a CEO stock sale and potential defense budget cuts. Here’s ...
Barchart on MSN4h
Wedbush: Defense Budget Cuts Will Help, Not Hurt Palantir Stock
U.S. defense stocks opened in the red on Thursday, Feb. 20 following reports that President Donald Trump’s administration has ...
Chimerix (NASDAQ:CMRX) Earns Outperform Rating from Wedbush
Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research note issued to investors on Tuesday,RTT News reports. They ...